Prognostic usefulness of planar
3-Iodobenzylguanidine
Aged
Female
Follow-Up Studies
Heart
/ innervation
Heart Failure
/ diagnostic imaging
Humans
Iodine Radioisotopes
Male
Middle Aged
Predictive Value of Tests
Prognosis
Radiopharmaceuticals
Stroke Volume
Survival Analysis
Sympathetic Nervous System
/ diagnostic imaging
Time Factors
Tomography, Emission-Computed, Single-Photon
123I-MIBG
cardiac death
congestive heart failure
prognosis
Journal
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
26
03
2019
accepted:
09
07
2019
pubmed:
31
8
2019
medline:
17
2
2022
entrez:
31
8
2019
Statut:
ppublish
Résumé
To evaluate whether planar Subjects from ADMIRE-HF were followed for approximately 5 years after imaging (964 subjects, median follow-up 62.7 months). Subjects were stratified according to the heart/mediastinum (H/M) ratio (< 1.60 vs ≥ 1.60) on planar During a median follow-up of 62.7 months, patients with H/M ≥ 1.60 were at significantly lower risk of death and arrhythmic events independently of LVEF values.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate whether planar
METHODS AND RESULTS
RESULTS
Subjects from ADMIRE-HF were followed for approximately 5 years after imaging (964 subjects, median follow-up 62.7 months). Subjects were stratified according to the heart/mediastinum (H/M) ratio (< 1.60 vs ≥ 1.60) on planar
CONCLUSIONS
CONCLUSIONS
During a median follow-up of 62.7 months, patients with H/M ≥ 1.60 were at significantly lower risk of death and arrhythmic events independently of LVEF values.
Identifiants
pubmed: 31468379
doi: 10.1007/s12350-019-01859-w
pii: 10.1007/s12350-019-01859-w
doi:
Substances chimiques
Iodine Radioisotopes
0
Radiopharmaceuticals
0
3-Iodobenzylguanidine
35MRW7B4AD
Iodine-123
8YWR746RPQ
Types de publication
Clinical Trial, Phase IV
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1490-1503Informations de copyright
© 2019. American Society of Nuclear Cardiology.
Références
Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, ADMIRE-HF Investigators, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective AdreView myocardial imaging for risk evaluation in heart failure (ADMIRE-HF) study. J Am Coll Cardiol 2010;55:2212-21. https://doi.org/10.1016/j.jacc.2010.01.014 .
doi: 10.1016/j.jacc.2010.01.014
pubmed: 20188504
Narula J, Gerson M, Thomas GS, Cerqueira MD, Jacobson AF. 123I-MIBG imaging for prediction of mortality and potentially fatal events in heart failure: The ADMIRE-HFX study. J Nucl Med 2015;56:1011-8. https://doi.org/10.2967/jnumed.115.156406 .
doi: 10.2967/jnumed.115.156406
pubmed: 26069309
Jacobson AF, Lombard J, Banerjee G, Camici PG.
doi: 10.1007/s12350-008-9008-2
pubmed: 19152136
Ketchum ES, Jacobson AF, Caldwell JH, Senior R, Cerqueira MD, Thomas GS, et al. Selective improvement in Seattle Heart Failure Model risk stratification using iodine-123 meta-iodobenzylguanidine imaging. J Nucl Cardiol 2012;19:1007-16. https://doi.org/10.1007/s12350-012-9603-0 .
doi: 10.1007/s12350-012-9603-0
pubmed: 22949270
Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917-23.
pubmed: 10452306
Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial
doi: 10.1093/eurheartj/ehn113
pubmed: 18349024
Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: Relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999;33:759-66.
doi: 10.1016/S0735-1097(98)00608-1
Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001;42:1757-67.
pubmed: 11752070
Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 1998;5:579-90.
doi: 10.1016/S1071-3581(98)90112-X
Nakajima K, Nakata T, Yamada T, Yamashina S, Momose M, Kasama S, et al. A prediction model for 5-year cardiac mortality in patients with chronic heart failure using
doi: 10.1007/s00259-014-2759-x
pubmed: 24663289
pmcid: 4122818
Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, DANISH Investigators, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;375:1221-30. https://doi.org/10.1056/NEJMoa1608029 .
doi: 10.1056/NEJMoa1608029
pubmed: 27571011
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;2013:e147-239. https://doi.org/10.1016/j.jacc.2013.05.019 .
doi: 10.1016/j.jacc.2013.05.019
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, ESC Scientific Document Group, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;2016:2129-200. https://doi.org/10.1093/eurheartj/ehw128 .
doi: 10.1093/eurheartj/ehw128
Barra S, Providencia R, Agarwal S. Do we need further clinical-effectiveness estimates to support the use of primary prevention implantable cardioverter-defibrillators in New York Heart Association class III patients? Int J Cardiol 2016;203:184-6. https://doi.org/10.1016/j.ijcard.2015.10.080 .
doi: 10.1016/j.ijcard.2015.10.080
pubmed: 26512835
Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004;95:754-63.
doi: 10.1161/01.RES.0000145047.14691.db
Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473-82.
doi: 10.1056/NEJMra000650
O’Day K, Levy WC, Johnson M, Jacobson AF. Cost-effectiveness analysis of iodine-123 meta-iodobenzylguanidine imaging for screening heart failure patients eligible for an implantable cardioverter defibrillator in the USA. Appl Health Econ Health Policy 2016;14:361-73. https://doi.org/10.1007/s40258-016-0234-5 .
doi: 10.1007/s40258-016-0234-5
pubmed: 26975999
pmcid: 4871910